Chiung-Tong Chen, Ph.D.
Institute of Biotechnology and Pharmaceutical Research
EDUCATIONPh.D., Pharmaceutics and Pharmaceutical Chemistry, Ohio State University, USA, 1997
M.S., Pharmacology, National Yang-Ming University, Taiwan, 1988
B.S., Pharmacy, China Medical University, Taiwan, 1986
PROFESSIONAL EXPERIENCESAdjunct Associate Professor, Institute of Life Science, National Defense Medical College, Taiwan (2006-present)
Director, Laboratory Animal Center, National Health Research Institutes, Taiwan (2005-present)
Associate Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2003-present)
Adjunct Assistant Professor, Institute of Medical Research, Taipei Medical University, Taiwan (2003-present)
Member, Board of Director, Bio21 Venture Capital Corporation, Taiwan (2003-2005)
Adjunct Assistant Professor, Institute of Life Science, National Defense Medical College, Taiwan, (2002-2006)
Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (1999-2003)
Research Associate, Department of Pharmacology, James H. Quillen College of Medicine, East Tennessee State University, USA (1997-1999)
Graduate Research Associate, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Ohio State University, USA (1992-1997)
Assistant Research Fellow, Institute of Biological Chemistry, Academia Sinica, Taiwan (1992)
Pharmacist, Institute of Research and Development, China Chemical & Pharmaceutical Group, Taiwan (1991)
Vice Researcher, Institute of Research and Development, China Chemical & Pharmaceutical Group, Taiwan (1990-1991)
RESEARCH INTERESTSDr. Chen considers “Translational Research” a broad research field covering from basic to clinical researches that ultimately benefit patients in any aspect and, therefore, his research interests have covered a broad spectrum from basic research to drug development such as the identification of tumor metastasis-associated molecules, establishment of diseased animal models (against cancer and diabetes) and drug discovery and development in the past few years. Professional disciplines such as pharmacokinetics, pharmacodynamics, pharmacology, pharmaceutics, molecular biology, laboratory animals, and drug discovery have been applied to the researches interested.
RESEARCH ACTIVITIES & ACCOMPLISHMENTSDr. Chen has established and led a research team responsible for executing the in vivo pharmacological evaluations of drug leads and candidates for drug discovery and development in the Division of Biotechnology and Pharmaceutical Research of the NHRI. Several drug leads and a few potential drug candidates against cancerous or diabetic diseases have been identified with promising pharmacological activities in animals. Dr. Chen has served as a member of the Board of Executive of The Chinese Society of Laboratory Animal Sciences since 2004 and a member of The Ethic Committee for Laboratory Animals of The Council of Agriculture of The Executive Yuan, Taiwan since 2006. In addition to the teaching activities, he has been invited for and given more than 30 talks in universities and hospitals in Taiwan since 2000. Dr. Chen has authored 45 scientific papers since 1990 and held the inventorship of 5 patents granted. He has served as an advisory editorial board member and reviewer for international and domestic journals as well as grant applications. Selected original papers published and patents granted are listed as follows.
SELECTED PUBLICATIONS1.Chuu JJ, Liu JM, Tsou MH, Huang CL, Chen CP, Wang HS and Chen CT*. Effects of paclitaxel and doxorubicin in histocultures of hepatocellular carcinomas. J. Biomedical Sci., 14:233-244, 2007.
2.Chang YW, Yeh TK, Lin KT, Chen WC, Yao HT, Lan SJ, Wu YS, Hsieh HP, Chen CM and Chen CT*. Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats. J. Food Drug Analysis, 14:329-333, 2006.
3.Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, ChangYL, Chen LT, Chen CT* and Chang JY*. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res., 64:4621-4628, 2004.
4.Wang HS, Hwang LL, Sue HF, Lee KM and Chen CT*. A simple quantitative method for evaluation of angiogenesis activity. ASSAY Drug Dev. Technol., 2(1):31-38, 2004.
5.Li WT, Hwang DR, Chen CP, Shen CW, Huang CL, Chen TW, Lin CH, Chang YL, Chang YY, Lo YK, Tseng HY, Lin CC, Song JS, Chen HC, Chen SJ, Wu SH and Chen CT*. Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. J. Med. Chem., 46(9):1706-1715, 2003.
6.Huang YC, Chen CT, Chen SC, Lai PH, Liang HC, Chang Y, Yu LC and Sung HW. A natural compound (Ginsenoside Re) isolated from Panax Ginseng as a novel angiogenic agent for tissue regeneration. Pharm. Res., 22(4):636-646, 2005.
7.Chen CT, Hwang LL, Chang JK and Dun NJ. Pressor effects of orexins injected intracisternally and to rostral ventrolateral medulla of anesthetized rats. Am. J. Physiol., 278:R692-R697, 2000.
8.Chen CT, Gan Y, Au JLS and Wientjes MG. Androgen-dependent andindependent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res., 58:2777-2783, 1998.
(* = Corresponding author)
PATENTUS patent pending: 6,903,104 B2 "Indolyl-3-yl-2-oxoacetamide compounds and methods of use thereof."
ROC Patent No. 281919 "??啉????"; Jun. 1st, 2007.
US Patent No. 7,129,359B2 "Imidazolidinone compounds"; Oct. 31, 2006.
US Patent No. 7,109,227 "Imidazolamino compounds"; Sep. 19, 2006.
ROC Patent No. 228417 "???????????????"; Mar. 1st, 2005.